Literature DB >> 10381298

A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease.

G Rothe1, A S Herr, J Stöhr, C Abletshauser, G Weidinger, G Schmitz.   

Abstract

Monocytes are recruited as the principal inflammatory cells into the atherosclerotic lesion. In a previous study we demonstrated that a low HDL-cholesterol and the apo E4 allele are associated with an increased proportion of blood monocytes that are characterized by a high expression of Fcgamma-RIIIa (CD16), a dim expression of the lipopolysaccharide (LPS) receptor (CD14) and a high expression of beta1- and beta2-integrins (Rothe et al. Arterioscler Thromb Vasc Cell Biol 1996;16:1437-1447). In this study, 79 hypercholesterolemic patients were treated either with the HMG CoA reductase inhibitor fluvastatin in combination with diet or with placebo and diet in a double-blind and randomized multicenter study, and monitored for the potential effects on the phenotype of peripheral blood monocytes. At baseline, in the whole group of hypercholesterolemic patients the population size of these more mature monocytes (CD14dimCD16+) was positively correlated to triglyceride (P = 0.003) and total serum cholesterol levels (P = 0.012) confirming our previous study. Fluvastatin treatment for 52 weeks was associated with a 24.2% reduction in LDL-cholesterol (P < 0.001) as well as a 40.7% decrease in the expression density of CD14 on all monocytes (P = 0.027). A 24.5% decrease (P < 0.001) of the population of less differentiated CD14brightCD16- monocytes and an 83.1% increase (P = 0.029) of the population of more differentiated CD14dimCD16+ monocytes further confirmed this modification of the phenotype of peripheral blood monocytes. The positive pre-study correlation of the CD14dimCD16+ monocyte subset to the serum cholesterol concentration, but inverse changes of both parameters under fluvastatin therapy, in conclusion indicate that fluvastatin exerts an as yet uncharacterized immunomodulatory effect on either monocyte maturation and differentiation, or extravasation which may also depend on the endothelial phenotype that is independent of the change in serum lipids.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10381298     DOI: 10.1016/s0021-9150(99)00061-1

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  25 in total

Review 1.  Antiinflammatory and immunomodulatory properties of statins.

Authors:  Ora Shovman; Yair Levy; Boris Gilburd; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 2.  Monocytes and Alzheimer's disease.

Authors:  Yu Feng; Lei Li; Xiao-Hong Sun
Journal:  Neurosci Bull       Date:  2011-04       Impact factor: 5.203

3.  Red Blood Cell Dysfunction Induced by High-Fat Diet: Potential Implications for Obesity-Related Atherosclerosis.

Authors:  Dusten Unruh; Ramprasad Srinivasan; Tyler Benson; Stephen Haigh; Danielle Coyle; Neil Batra; Ryan Keil; Robert Sturm; Victor Blanco; Mary Palascak; Robert S Franco; Wilson Tong; Tapan Chatterjee; David Y Hui; W Sean Davidson; Bruce J Aronow; Theodosia Kalfa; David Manka; Abigail Peairs; Andra Blomkalns; David J Fulton; Julia E Brittain; Neal L Weintraub; Vladimir Y Bogdanov
Journal:  Circulation       Date:  2015-10-14       Impact factor: 29.690

4.  Effect of CD14 promoter polymorphism and H. pylori infection and its clinical outcomes on circulating CD14.

Authors:  J Karhukorpi; Y Yan; S Niemela; J Valtonen; P Koistinen; T Joensuu; P Saikku; R Karttunen
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

Review 5.  Monocyte heterogeneity in cardiovascular disease.

Authors:  Peter Libby; Matthias Nahrendorf; Filip K Swirski
Journal:  Semin Immunopathol       Date:  2013-07-10       Impact factor: 9.623

Review 6.  Intracellular cholesterol and phospholipid trafficking: comparable mechanisms in macrophages and neuronal cells.

Authors:  G Schmitz; E Orsó
Journal:  Neurochem Res       Date:  2001-09       Impact factor: 3.996

Review 7.  Fluvastatin: a review of its use in lipid disorders.

Authors:  H D Langtry; A Markham
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

Review 8.  Making a difference: monocyte heterogeneity in cardiovascular disease.

Authors:  Ingo Hilgendorf; Filip K Swirski
Journal:  Curr Atheroscler Rep       Date:  2012-10       Impact factor: 5.113

9.  Heterogeneity of peripheral blood monocytes, endothelial dysfunction and subclinical atherosclerosis in patients with systemic lupus erythematosus.

Authors:  T P Mikołajczyk; G Osmenda; B Batko; G Wilk; M Krezelok; D Skiba; T Sliwa; J R Pryjma; T J Guzik
Journal:  Lupus       Date:  2015-08-06       Impact factor: 2.911

Review 10.  Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis.

Authors:  Filip K Swirski; Ralph Weissleder; Mikael J Pittet
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-04-16       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.